The Priority Review

Tag

Shanghai Henlius Biotech

1 story

  1. Clinical trials

    Shanghai Henlius Biotech registers Phase II/III study of HLX37 in first-line NSCLC

    The study, first posted on ClinicalTrials.gov on October 8, 2026, plans to enroll 1438 participants and plans to begin recruiting on November 30, 2026. It compares two doses of HLX37 combined with chemotherapy to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer.